Journal
DRUG DISCOVERY TODAY
Volume 27, Issue 1, Pages 280-291Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.07.025
Keywords
PET imaging; Drug development; Drug discovery; Receptor occupancy; Biodistribution; Pharmacokinetics; Pharmacodynamics; Drug treatment monitoring; Validation of target engagement
Categories
Funding
- LKC Medicine Imaging Probe Development Platform, Singapore
- Cognitive Neuroimaging Centre (CONIC) at Nanyang Technological University, Singapore
- Lee Kong Chian School of Medicine
- NTU Austrian Institute of Technology
- Medical University of Vienna internal grant [NAM/15006]
Ask authors/readers for more resources
Positron emission tomography (PET) is a widely used nuclear functional imaging technique, particularly in central nervous system (CNS) and oncological disorders. It can accelerate drug discovery and development by monitoring drug distribution and effects, providing important references for clinical application.
Positron emission tomography (PET) is an extensively used nuclear functional imaging technique, especially for central nervous system (CNS) and oncological disorders. Currently, drug development is a lengthy and costly pursuit. Imaging with PET radiotracers could be an effective way to hasten drug discovery and advancement, because it facilitates the monitoring of key facets, such as receptor occupancy quantification, drug biodistribution, pharmacokinetic (PK) analyses, validation of target engagement, treatment monitoring, and measurement of neurotransmitter concentrations. These parameters demand careful analyses for the robust appraisal of newly formulated drugs during preclinical and clinical trials. In this review, we discuss the usage of PET imaging in radiopharma-ceutical development; drug development approaches with PET imaging; and PET developments in oncological and cardiac drug discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available